Author: Ravi Shankar

New York and Dubai, October 20, 2026. VEON Ltd. (Nasdaq: VEON), a global digital operator, today confirmed the cancellation of approximately 1.5% of its total issued shares.

Today’s cancellation of 26,951,230 common shares (equivalent to 1,078,049 ADSs) is pursuant to VEON’s ongoing share buyback program announced on September 23, 2026 to buy back and cancel 3.9% of VEON’s outstanding shares.

About VEON
VEON is a digital operator that provides connectivity and digital services to over 150 million connectivity and more than 228 million digital customers. Operating across five countries that are home to 550 million consumers, more than 6% of the world’s population, VEON is transforming lives through technology-driven services that empower individuals and drive economic growth. VEON is listed on NASDAQ. For more information, visit: https://www.veon.com.

Forward-Looking Statements
This release contains “forward-looking statements”, within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements relating to the execution and/or impact of the buyback of the VEON Group’s ADSs and shares and the cancellation of such shares. There are numerous risks and uncertainties that could cause actual results and performance to differ materially from those expressed by such statements, including risks relating to uncertainty over the execution and/or impact of the buyback of the VEON Group’s ADSs and shares, among others discussed in the section entitled “Risk Factors” in VEON’s 2025 Form 20-F filed with the SEC on March 16, 2026 and other public filings made by VEON with the SEC. There is no assurance that the buyback of VEON ADSs and shares and the cancellation of such shares will be completed or that other events described in any forward-looking statement will materialize. The forward-looking statements contained herein speak only as of the date of this release and VEON disclaims any obligation to update them, except as required by law.

TORONTO, Oct. 20, 2026 (GLOBE NEWSWIRE) — Prospectiva Resources Ltd. (TSX-V: PSVA) (“Prospectiva” or the “Company”) a Brazil-focused copper and gold exploration company advancing a portfolio of 100%-owned projects in the highly-prospective but underexplored Borborema Belt, northeastern Brazil, is pleased to report initial assay results from the first three diamond drill holes of its maiden exploration programme at its flagship São Francisco Copper-Gold Project in Pernambuco State. All three holes intersected massive, semi-massive and heavy disseminated copper-bearing sulphide mineralisation. These results confirm that the mineralised zone is strongly consistent with the geophysical anomalies generated by the recently completed Fixed Loop Electromagnetic (FLEM) survey.

Highlights:

• Key mineralised intervals from the initial three drill holes include;
  • SF_26_003 intersected 7.15 m at 4.78% Cu, 0.19 g/t Au and 0.65% Zn
    including 3.60 m at 9.17% Cu, 0.35 g/t Au and 1.17% Zn

• • SF_26_002 intersected 2.50 m at 3.24% Cu, 0.42 g/t Au and 0.44% Zn
    including 1.50 m at 5.05% Cu, 0.69 g/t Au and 0.68% Zn

• • SF_26_001 intersected 4.00 m at 1.93% Cu, 0.23 g/t Au and 0.38% Zn
    including 1.10 m at 6.03% Cu, 0.30 g/t Au and 0.68% Zn

• These initial results indicate that the high-grade near-surface copper mineralisation continues from the surface “discovery outcrop”, to these current drill holes located approximately 600 metres to the east, along the interpreted down-plunge trend.
• Drilling is ongoing with two drill rigs now active on site as the Company works towards completing this initial 10-hole drilling programme.

Dan James, Chief Executive Officer of Prospectiva said, “The first three holes of our maiden drill programme at São Francisco have returned very strong results with all three intersecting high-grade copper mineralisation at shallow depths. These intersections, when combined with the historical drilling results, suggests good continuity of high-grade, near-surface mineralisation. The results also include encouraging associated gold and zinc grades. Our recent structural mapping and geophysical surveys have been key to defining drill targets, with drilling consistently intersecting mineralisation at the target horizons.

Our new geological work also suggests that we are seeing a stratabound system, interpreted to be VMS-style. These systems typically occur as clusters, raising the potential for further zones of mineralisation within the same geological setting.

We now have two drill rigs active on the project and we are systematically drilling eastwards to extend the zone of known mineralisation at SF1. In parallel, our field team is undertaking further ground geophysics on targets around SF1. We look forward to reporting further drill results as we progress to the completion of the Phase 1 drill programme”.

Detailed Information

To date, Prospectiva has completed six planned diamond drill holes (SF_26_001 to SF_26_006). Assay results have been received for the first three holes, with results from the remaining completed holes pending. The fully funded programme is on-going, now with two drill rigs on site, and is expected to complete in mid-Q4 2026.

Drilling is progressing eastwards along the interpreted down-plunge extension of the mineralised system, as guided by historical exploration work, a new structural model, FLEM and Downhole Electromagnetic (DHEM) surveys all completed by Prospectiva over the last 6 months.

São Francisco – Initial 2026 Diamond Drilling Results

Table 1. Selected initial diamond drilling results.

Drillhole	From (m)	To (m)	Interval (m)	Cu (%)	Au (g/t)	Zn (%)
SF_26_001	66.00	70.00	4.00	1.93	0.23	0.38
including	67.05	68.15	1.10	6.03	0.3	0.68
SF_26_002	75.00	77.50	2.50	3.24	0.42	0.44
including	76.00	77.50	1.50	5.05	0.69	0.68
SF_26_003	85.85	93.00	7.15	4.78	0.19	0.65
including	85.85	89.45	3.60	9.17	0.35	1.17
which includes	88.70	89.45	0.75	15.9	0.52	1.54
SF_26_004*	Awaiting assays
SF_26_004b	Awaiting assays
SF_26_005	Awaiting assays
SF_26_006	Awaiting assays
SF_26_007	Hole in progress
SF_26_008	Hole in progress

*SF_26_004 was terminated at approximately 40 m due to excessive drillhole deviation, following intersection of the targeted mineralised horizon. The hole was subsequently redrilled as SF_26_004b.

Note: Significant intersections are calculated using a nominal lower cut-off grade of 0.20% Cu. All reported intervals comprise contiguous samples exceeding the cut-off, with no internal dilution applied. Copper, gold and zinc grades represent length-weighted averages. Reported intervals are downhole lengths; true widths have not yet been established.

Table 2. Drill collar details of selected initial diamond drilling results.

Drillhole	Eastings	Northings	Elevation (m)	Dip (°)	Azimuth (°)
SF_26_001	650072	9162102	613	-55	185
SF_26_002	650075	9162107	613	-55	110
SF_26_003	650248	9162101	624	-68	180

Hole locations given in WGS84 UTM Zone 24S.

Full project details, including the drill collar plan, can be found at:
https://prospectiva-resources.com/projects/sao-francisco.

Photo 1. Active drilling at São Francisco of drill hole SF_26_003 in September 2026.

Photo 2. Uncut drill core of massive sulphide mineralisation at SF_26_003 from the high-grade interval between 85.85 and 93.00m. Mineralisation is predominantly chalcopyrite and minor pyrrhotite, with lithic breccia clasts, at 89.40m.

Interpretation and Exploration Programme

Prospectiva has completed a detailed geological and structural review of the São Francisco mineralised system, incorporating historical drill-core relogging, field mapping, structural measurements and geophysical interpretation. The review, undertaken with specialist geological consultants, has refined the Company’s three-dimensional geological model and is guiding the ongoing drilling programme.

Structural interpretation and plunging mineralised shoots

The São Francisco mineralisation comprises massive to semi-massive pyrrhotite–chalcopyrite hosted within a deformed sequence of metamorphosed schists and gneisses. The stratabound sulphide mineralisation is interpreted to have undergone significant deformation and local remobilisation, forming broad and elongated mineralised horizons parallel to fold axes, which is likely hosted within fold hinges. Historical drilling and structural measurements suggest that the mineralised system is associated with a gently east-plunging structural trend of approximately 5–15°. This interpretation provides a framework for targeting potential extensions of known mineralisation.

Ongoing drilling and target generation

The current programme is designed to test down-plunge extensions of the mineralisation, gaps between historical drill intersections and new geophysical targets identified through FLEM and DHEM surveys.

The first three drill holes intersected massive to semi-massive copper-bearing sulphides at depths broadly consistent with the revised geological interpretation (between 60 and 95m depth). These results provide strong support for the structural model, while further drilling is required to establish continuity for resource definition.

Oriented drill core and systematic structural measurements are being used to refine the geometry of foliation, fold axes and mineral lineations. These observations, together with electromagnetic survey results, are being incorporated into the evolving three-dimensional geological model to guide subsequent drill targeting.

Broader exploration potential

The principal sulphide-bearing horizon is interpreted to represent a structurally modified, potentially remobilised VMS-style mineralising system, hosted within an approximately 60 m thick prospective schist package. This provides a geological framework for tracing favourable stratigraphy along strike and down plunge. Prospectiva’s structural review has identified the potential for additional sulphide mineralisation beyond the currently drilled areas, including prospective positions around the interpreted fold hinge and elsewhere within the broader stratigraphic sequence. Prospectiva intends to continue integrating geological mapping, structural interpretation, geochemical sampling and electromagnetic surveys to evaluate these opportunities while advancing drilling along the established São Francisco mineralised trend.

Sampling, Analytical Procedures and Quality Assurance

Drill core samples were selected based on mineralisation, lithological or alteration boundaries and collected by Prospectiva personnel, labelled and placed in sealed sample bags before delivery to ALS Parauapebas, an independent sample preparation laboratory. Following preparation using ALS method PREP-31, sample pulps were forwarded to ALS Lima, Peru, for analytical testing. Gold was analysed by 50 g fire assay with an atomic absorption finish (Au-AA24). Multi-element analysis was completed using four-acid digestion followed by a combination of ICP-MS and ICP-AES (ME-MS61). Samples exceeding the upper analytical limits for copper and zinc were re-analysed using ore-grade methods (Cu-OG62 and Zn-OG62, as applicable).

Prospectiva maintains a quality assurance and quality control (QA/QC) programme incorporating the insertion of certified reference materials (CRMs), blanks and duplicate samples into the analytical sample stream. QA/QC results are reviewed alongside the laboratory’s internal quality-control data to assess the reliability of the analytical results. The Qualified Person has reviewed the available analytical results and associated QA/QC information to assess their suitability for public disclosure.

Qualified Person

The scientific and technical information contained in this press release has been reviewed and approved by Robert Selwyn, MGeol, CGeol, FGS, a Qualified Person as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”). Robert Selwyn is Chief Geologist and a non-independent consultant to Prospectiva.

ON BEHALF OF THE BOARD OF DIRECTORS OF PROSPECTIVA RESOURCES LTD.
“Dan James” CEO and Director

For more information, please contact:
Dan James, Chief Executive Officer
Tel: +1 (647) 947-2145
Email: ir@prospectiva-resources.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

About Prospectiva Resources Ltd.

Prospectiva Resources is a Brazil-focused copper and gold exploration company advancing a district-scale portfolio of 100%-owned projects across the highly prospective but underexplored Borborema Province in northeastern Brazil. The Company’s land package comprises 21 mineral exploration licences covering approximately 343 km² across the states of Pernambuco and Paraíba with current focus on its flagship São Francisco Copper-Gold Project.

São Francisco is the Company’s priority exploration asset. Geological interpretation, historical IP geophysics and Prospectiva’s recent FLEM survey have defined a prospective geological and geophysical corridor extending for approximately 3 km. Mineralisation is high-grade, with a historical best intersection of 7.50 m @ 6.41% Cu & 0.36 g/t Au (SF_006), and near-surface.

Prospectiva is undertaking a diamond drilling programme to test newly identified electromagnetic conductors and other priority targets within the approximately 3 km prospective geological and geophysical corridor. The programme forms part of the Company’s strategy to advance São Francisco towards the potential definition of an initial Mineral Resource in 2027.

www.prospectiva-resources.com

Forward looking statements: This news release includes certain “forward-looking information” within the meaning of Canadian securities legislation. Forward-looking statements include predictions, projections and forecasts and are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “forecast”, “expect”, “potential”, “project”, “target”, “schedule”, “budget” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions and includes the negatives thereof. Forward-Looking Statements are not guarantees of future performance. They are based on the opinions, estimates and assumptions of the Company’s management as of the date of the news release, having regard to management’s experience and perception of trends, current conditions and expected developments, and are inherently subject to significant risks, uncertainties, contingencies and other factors, many of which are beyond the Company’s control. All Forward-Looking Statements in the news release speak only as of the date of the news release.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/35efdb26-3023-412e-ab89-ea511ae102b6

https://www.globenewswire.com/NewsRoom/AttachmentNg/16bd83f1-2fb4-4162-9f29-89d2a7c04261

RALEIGH, N.C., Oct. 20, 2026 (GLOBE NEWSWIRE) — Slate Medicines, Inc. (“Slate”), a clinical-stage biotechnology company committed to advancing innovative new therapies that may broaden the treatment paradigm and potentially improve outcomes for people with migraine and other headache disorders, today announced the appointment of Stephen K. Brannan, MD, and John D. Young to the company’s Board of Directors. Dr. Brannan brings more than 25 years of clinical development experience in CNS disorders and most recently served as the Chief Medical Officer of Karuna Therapeutics. Mr. Young brings more than 35 years of biopharmaceutical industry experience, including serving as a member of the Executive Leadership Team at Pfizer, most recently as Group President and Chief Business Officer.

“We are pleased to welcome Stephen and John to the Slate Medicines Board, both of whom have complementary experience that is well matched to our priorities,” said Gregory Oakes, MBA, Chief Executive Officer of Slate Medicines. “Stephen has helped bring multiple CNS treatments from the clinic to approval, while John has shaped corporate strategy, partnerships and portfolio decisions at a leading global pharmaceutical company. Their guidance will be invaluable as we advance SLTE-1009 as well as our portfolio and work to bring much-needed new treatment options to migraine patients who remain underserved by current therapies.”

Dr. Brannan served as Chief Medical Officer of Karuna Therapeutics from 2017 until 2024, overseeing clinical development of KarXT (xanomeline and trospium) through Phase 3 trials in schizophrenia, the program that led to the approval of Cobenfy^® (xanomeline and trospium chloride). Earlier in his career, he held clinical and medical leadership roles at Forum Pharmaceuticals, Takeda (including Therapeutic Area Head for CNS), Novartis, Cyberonics (now LivaNova) and Eli Lilly. Board-certified in psychiatry, Dr. Brannan received his AB from Harvard University and his MD from The University of Texas Southwestern Medical School.

“Migraine remains a disease where many people are still looking for better options,” said Dr. Brannan. “SLTE-1009 is a potentially differentiated migraine preventative, and I look forward to working with the Slate team to apply the best practices needed for the successful development of CNS programs to realize the full potential of this innovative treatment option.”

Mr. Young retired from Pfizer in 2022 after a 35-year career, most recently as Group President and Chief Business Officer. A member of Pfizer’s Executive Leadership Team, Mr. Young has deep experience in corporate strategy, business development, portfolio management, and commercialization. Mr. Young currently serves on the boards of Novartis AG and Johnson Controls International. He holds a BSc in Biological Sciences from the University of Glasgow and an MBA from Strathclyde Graduate Business School.

“Slate has developed a compelling portfolio of assets that has the potential to impact the lives of migraine patients globally,” said Mr. Young. “I look forward to working with the Slate board of directors and broader team as they advance their programs.”

About Slate Medicines, Inc.

Slate Medicines is a clinical-stage biotechnology company committed to advancing innovative new therapies that may broaden the treatment paradigm and potentially improve outcomes for people with migraine and other headache disorders. Slate is advancing a portfolio of potentially best-in-class therapeutics, led by SLTE-1009, a clinical-stage anti-PACAP/VIP monoclonal antibody designed to enable subcutaneous, infrequent dosing. For more information, please visit the Slate Medicines website.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “plans,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning the potential of SLTE-1009 and Slate’s other product candidates to expand treatment options for migraine and other headache disorders; the potential for Slate’s portfolio of product candidates, including SLTE-1009, to be best-in-class or differentiated; and Slate’s research, development and regulatory plans for its product candidates. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation, risks with respect to: the ability of Slate to retain, attract and hire key personnel; the potential failure to identify additional product candidates and develop or commercialize marketable products; the early stage of Slate’s development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process; interim, topline and preliminary data may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data; Slate’s product candidates may cause serious adverse side effects; inability to maintain existing or future collaborations, or the failure of these collaborations; Slate’s reliance on third parties, including for the manufacture of materials for research programs, preclinical and clinical studies; failure to obtain U.S. or international marketing approval; ongoing regulatory obligations; effects of significant competition; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability lawsuits; securities class action litigation; the impact of general economic conditions on its business and operations, including Slate’s preclinical studies and clinical trials; the possibility of system failures or security breaches; and risks relating to intellectual property. These forward-looking statements speak only as of the date hereof, and Slate disclaims any obligation to update these statements except as may be required by law.

Media and Investor Contacts

ICR Healthcare
slate@icrhealthcare.com

YOL104-2 is a bioengineered, trivalent, multifunctional peptibody incorporating a core interferon-mimetic with the potential to be a first-in-class therapy for Ocular Surface Squamous Neoplasia (OSSN)

Visara is a majority-owned ophthalmology subsidiary of NovaBridge Biosciences

ROCKVILLE, Md., Oct. 20, 2026 (GLOBE NEWSWIRE) — Visara, Inc. (“Visara”), a majority-owned ophthalmology subsidiary of NovaBridge Biosciences, Inc. (“NovaBridge”) (NASDAQ: NBP), today announced that it has entered into an asset purchase option agreement (the “Option Agreement”) with YOLO Immune (“YOLO”). The Option Agreement provides Visara with an exclusive option to acquire worldwide rights to the YOL104 Program and develop and commercialize YOL104-2 for ocular surface squamous neoplasia (OSSN). YOL104-2 is a trivalent interferon alpha (IFN-α) peptibody currently under investigation for the treatment of OSSN.

“YOL104-2 represents an attractive potential addition to Visara’s pipeline and aligns well with our strategy to build a differentiated ophthalmology portfolio,” said Jeffrey Nau, Ph.D., MMS, President and Chief Executive Officer of Visara. “Through this agreement, we have secured the opportunity to potentially expand our development efforts into an additional area of significant unmet need where there is currently no FDA approved therapy.”

“This transaction demonstrates the NovaBridge approach to disciplined portfolio building: identifying differentiated innovation, pairing it with focused operating expertise and advancing opportunities through the structure best suited to each asset,” said Srishti Gupta, M.D., M.P.P., Chief Executive Officer of NovaBridge. “By securing an exclusive option to acquire YOL104-2, Visara gains the opportunity to further evaluate a differentiated program in ocular surface disease while maintaining flexibility in capital allocation and portfolio development.”

Under the terms of the Option Agreement, Visara will make an upfront payment in exchange for an exclusive option to acquire worldwide title and ownership of the YOL104 Program. If Visara exercises the option and completes the acquisition, YOLO would receive an exercise payment and would be eligible for development, regulatory and commercial milestone payments, as well as tiered royalties on net sales. Additional financial terms were not disclosed.

About YOL104-2
YOL-104-2 is a bioengineered, trivalent, multifunctional peptibody incorporating a core interferon-mimetic for the treatment of ocular surface squamous neoplasia (OSSN).

About Ocular Surface Squamous Neoplasia (OSSN)
Ocular Surface Squamous Neoplasia (OSSN) is diagnosis that includes a wide range of cancerous and precancerous growths on the surface of the cornea and conjunctiva. It is linked to sun exposure, HPV infection and a weakened immune system, and it is the most common non-pigmented tumor of the ocular surface.

About Visara
Visara is a clinical stage biotechnology company dedicated to developing next-generation biologic therapies for ophthalmic diseases affecting both the front and back of the eye. From the cornea to the retina, Visara pursues the full spectrum of ocular disease as vision is irreplaceable, and the unmet need is profound. Visara is a majority-owned ophthalmology subsidiary of NovaBridge Biosciences (NASDAQ: NBP). Its pipeline includes VIS-101, a tetravalent VEGF-A × ANG-2 peptibody being developed for neovascular retinal diseases, and VIS-102, a next-generation modified recombinant human nerve growth factor therapy being developed for neurotrophic keratitis.

About NovaBridge Biosciences
NovaBridge Biosciences (“NovaBridge”) (NASDAQ: NBP) is a global biotechnology company advancing a portfolio of therapeutic programs in oncology and ophthalmology. The Company identifies differentiated therapeutic opportunities, generates value-defining clinical evidence, and applies the development, financing and partnering strategy best suited to each program.

NovaBridge’s portfolio is led by givastomig, a Claudin 18.2 × 4-1BB bispecific antibody being developed for the potential treatment of gastrointestinal malignancies, and Visara, its majority-owned ophthalmology subsidiary. Through Visara, NovaBridge is building a diversified ophthalmology franchise designed to address unmet needs across diseases of the front and back of the eye.

NovaBridge’s objective is to build a sustainable biotechnology company by repeatedly identifying differentiated innovation, advancing it efficiently, and bringing novel therapies to patients through the path best suited to each opportunity.

For more information, please visit www.novabridge.com and follow us on LinkedIn.

Forward Looking Statements
This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “believes,” “designed to,” “anticipates,” “future,” “intends,” “plans,” “potential,” “estimates,” “confident,” and similar terms or the negative thereof. NovaBridge and Visara may also make written or oral forward-looking statements in NovaBridge’s periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about NovaBridge’s beliefs and expectations, are forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding: the potential exercise of the option to acquire and development of YOL104-2; the potential achievement of development, regulatory and commercial milestones under the Option Agreement; expected milestone and royalty payments under the Option Agreement; the potential benefits of Visara’s product candidates, including VIS-101 and VIS-102; and the strategy, clinical development, plans, timing, results, safety and efficacy of Visara’s drug candidates, including VIS-101 and VIS-102. Forward-looking statements involve inherent risks and uncertainties that may cause actual results to differ materially from those contained in these forward-looking statements, including but not limited to the following: NovaBridge’s or Visara’s ability to demonstrate the safety and efficacy of their drug candidates; the clinical results for their drug candidates, which may or may not support further development or New Drug Application/Biologics License Application approval or eligibility for accelerated approval pathway or receipt of accelerated approval; the content and timing of decisions made by the relevant regulatory authorities, including the FDA, regarding regulatory approval of NovaBridge’s or Visara’s drug candidates; NovaBridge’s or Visara’s ability to achieve commercial success for their drug candidates, if approved; NovaBridge’s or Visara’s ability to obtain and maintain protection of intellectual property for their technology and drugs; NovaBridge’s or Visara’s reliance on third parties to conduct drug development, manufacturing and other services; NovaBridge’s or Visara’s limited operating history and their ability to obtain additional funding for operations and to complete the development and commercialization of their drug candidates; the impact of macroeconomic conditions, including inflation, tariffs, volatile interest rates, regulatory uncertainty, potential government shutdowns, volatility in the capital markets, and regional and other global events, including ongoing armed conflicts in different regions of the world; and those risks more fully discussed in the “Risk Factors” section in NovaBridge’s annual report on Form 20-F filed with the SEC on April 7, 2026, and amended on June 16, 2026, as well as the discussions of potential risks, uncertainties, and other important factors in NovaBridge’s subsequent filings with the SEC. All forward-looking statements are based on information currently available to NovaBridge. NovaBridge undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law.

NovaBridge Investor & Media Contacts

Investors:
Bill Begien, SVP, Investor Relations
+1-240-745-6330
bill.begien@novabridge.com
IR@novabridge.com

Media Inquiries:
Eric Van Zanten, VP, Communications
+1-610-529-6219
eric.vanzanten@novabridge.com

Katy, Texas, Oct. 20, 2026 (GLOBE NEWSWIRE) — CW Petroleum Corp^® (OTCQB: CWPE) (the “Company” or “CWPE”), a leading provider of Specialty Renewable and Hydrocarbon Motor Fuels, today announces to its investors and future investors that it has received approval from the United States Patent and Trademark Office (USPTO) for its three Trademark applications.

The USPTO awarded CW Petroleum Corp^® the following approved trademarks:

CW Logo – US SN# 98593898

CW Petroleum Corp (Standard Character Mark) – US SN# 99035623

CW (Standard Character Mark) – US SN# 99035607

Management Commentary:

Chief Executive Officer Christopher Williams shared a major milestone today, celebrating the official approval of all three USPTO applications. “This is a thrilling moment for us,” Williams stated. “These approvals give us the green light to fully launch our premium, reformulated High-octane (91, 92, 93), NO-ethanol gasoline branding plan. Our specialized fuels are completely EPA-approved and engineered perfectly for marine, classic cars, performance vehicles, and small engines. We are excited to begin our expansion, bringing the CW Petroleum Corp^® brand to retail and distributor networks across the great State of Texas. As we drive this growth, we are actively looking to secure expansion capital and moving towards an uplist on the Nasdaq or NYSE.”

Additional accurate information about the Company can be found on the OTC Markets website at the following links and on the EDGAR filing website provided by the Securities and Exchange Commission:

CWPE Overview
CWPE Security Detail
CWPE Financials
CWPE News
CWPE Disclosures

SEC Filings

For additional information, visit our website at cwpetroleumcorp.com, email: investor@cwpetroleumcorp.com , or call 281-817-8099

About CW Petroleum Corp^®

CW Petroleum Corp^®, a Texas corporation, was founded by Christopher Williams and began operations in 2011. CW Petroleum Corp^®, a Wyoming corporation, was incorporated in April 2018 and has acquired the Texas corporation as a wholly-owned subsidiary. CW Petroleum Corp^® supplies and distributes Biodiesel, Biodiesel Blends, Renewable Gasoline, and NO ETHANOL High Octane (91, 92, 93) On-Road Reformulated Gasoline to distributors, convenience stores, marinas, and end-users.

Forward-Looking Statements

Certain statements in this press release may contain “forward-looking statements” regarding future events and our future results. All statements other than statements of historical facts are statements that could be deemed to be forward-looking statements. These statements are based on current expectations, estimates, forecasts, and projections about the oil and gas markets, energy markets, and other markets in which we operate and the beliefs and assumptions of our management. Words such as “expects,” “anticipates,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “endeavors,” “strives,” “may,” or variations of such words and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements are subject to a number of risks, uncertainties, and assumptions that are difficult to predict, estimate, or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Such risks and uncertainties include those factors described in the Company’s most recent annual report on Form 1-K, which may be amended or supplemented by subsequent semiannual reports on Form 1-SA or other reports filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements. For more information, please refer to the Company’s filings with the Securities and Exchange Commission.

No Offer or Solicitation

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Blossom Gold Inc. (TSX: BGAU; OTCQX: BGAUF), a precious metals exploration and development company, has qualified to trade on the OTCQX® Best Market. Blossom Gold Inc. upgraded to OTCQX from the Pink Limited™ Market.

Blossom Gold Inc. begins trading today on OTCQX under the symbol “BGAUF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

Upgrading to the OTCQX Market is an important step for companies seeking to provide transparent trading for their U.S. investors. For companies listed on a qualified international exchange, streamlined market standards enable them to utilize their home market reporting to make their information available in the U.S. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance and demonstrate compliance with applicable securities laws.

“Joining the OTCQX Best Market is an important step in broadening Blossom Gold’s shareholder base and improving trading access for our U.S.-based investors,” said Rick Winters, Chief Executive Officer of Blossom Gold. “As we continue to advance the Rosebud Project toward development, this trading platform gives U.S. investors a more direct and efficient way to participate in our story alongside our existing TSX shareholders.”

Trading in non-U.S. North American securities on OTC Markets reached $23.4 billion in the second quarter of 2026, representing an 88.25% increase over Q2 2025. OTC Markets recorded $453.34 billion in total dollar volume in the first half of the year. Canada ranked among the top home markets by trading volume during the quarter, highlighting sustained U.S. investor demand for internationally listed names.

About Blossom Gold Inc.

Blossom Gold is a Canadian-based precious metals exploration and development company that recently began trading on the TSX under the symbol BGAU. Blossom Gold acquired the Rosebud Project in connection with the TSX-listing and will be focused on the exploration and development of the project. The Rosebud Project includes the former Rosebud Mine, where mining was conducted from 1997 through 2000 by the Rosebud Mining Company, a Newmont-Hecla joint venture, using underground mining methods where the mine operated at a cut-off grade of approximately 0.2 opt Au (6.8 gAu/t), when gold prices ranged from US$250 to US$350/oz; with mined material truck-hauled approximately 120 miles to an existing Newmont oxide mill for processing.

The current vision for the Rosebud Project is to evaluate the remaining higher-grade mineralization and the surrounding larger volume of lower grade mineralization as a potential open pit mining operation with on-site, heap-leach processing and recovery of gold and silver. The Rosebud Project currently hosts an Inferred Mineral Resource of 70.755 million tons grading 0.62gAu/t (0.018opt Au) and 6.49gAg/t (0.189opt Ag) for 1.28 million ounces of gold and 13.4 million ounces of silver. The mineral resource estimate was open pit constrained using long term gold and silver prices of US$2,500 and US$35 per ounce respectively. The deposit is open in all directions.

Further details on Blossom and the Rosebud Project, including the technical report titled “Mineral Resource Estimate for the Rosebud Property, Pershing County, NV, USA” by Northern Lights Mining LLC, with a report date of December 17, 2025 and an effective date of November 1, 2025, can be found under the Company’s profile on SEDAR+ at www.sedarplus.com and the Company’s website at www.blossomgold.com.

About OTC Markets Group Inc.

OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our public markets: OTCQX® Best Market, OTCQB® Venture Market, OTCID™ Basic Market and Pink Limited™ Market. Our OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets.

OTC Link ATS, OTC Link ECN, OTC Link NQB, OTC Overnight® and MOON ATS® are each an SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC.

To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com

New appointments of global quantum experts Shor, Paler, Devitt and Izmaylov further validate Zapata’s approach to quantum software

BOSTON, Oct. 20, 2026 (GLOBE NEWSWIRE) — Zapata Quantum (OTCQB: ZPTA) (“Zapata”, “Zapata Quantum” or the “Company”), a pioneer in quantum computing application and algorithm development, today announced the appointment of Dr. Peter Shor and other notable scientists to its Scientific Advisory Board (SAB). Shor is the MIT mathematician whose landmark 1994 algorithm, now known as Shor’s algorithm, showed how quantum computers could solve a major computational problem far faster than the best-known classical methods, helping launch the modern field of quantum computing.

“Quantum computers will only be as useful as the applications we run on them. As hardware matures toward fault tolerance, it’s critical that we discover and develop new algorithms to truly unlock the power of this new technology,” said Dr. Shor. “I’m excited about the work Zapata is doing in this area and look forward to helping guide those efforts.”

The new SAB members will advise on Zapata’s scientific and technical direction, including the further development of Quantum Pilot™, its hardware-agnostic platform combining decision intelligence and engineering to discover and develop quantum applications.

In addition to Dr. Shor, other distinguished scientists joining the SAB include Dr. Alexandru Paler, Associate Professor of Computer Science at Aalto University in Finland; Dr. Simon Devitt, Professor and Director of the Centre for Quantum Software and Information (QSI) at the University of Technology, Sydney; and Dr. Artur Izmaylov, Professor of Theoretical and Computational Chemistry at the University of Toronto.

“Dr. Shor’s work is the reason this entire field exists. His discovery of quantum algorithmic advantage is the foundational proof point the industry has been built upon, and having his guidance regarding our scientific direction is strong validation of our approach,” said Sumit Kapur, CEO of Zapata Quantum. “Together with Dr. Paler, Dr. Devitt and Dr. Izmaylov, our expanded SAB reinforces Zapata’s leadership across the most technically demanding layers of the quantum software stack.”

Dr. Peter Shor: The Scientific Foundation of Quantum Advantage

Dr. Shor is the Henry Adams Morss and Henry Adams Morss, Jr. Professor of Applied Mathematics at MIT and one of the most decorated scientists in quantum computing. In 1994, he discovered Shor’s algorithm, proving a quantum computer could factor large integers — the mathematical problem underlying RSA encryption — exponentially faster than any classical computer, a breakthrough that ignited the field and made quantum-safe cybersecurity one of its highest-stakes challenges. In 1995, he introduced the first quantum error-correcting code, the foundational insight behind fault-tolerant quantum architectures. His honors include a MacArthur Fellowship, the Gödel Prize, and the Breakthrough Prize in Fundamental Physics.

Shor’s appointment places the discoverer of quantum computational advantage as a key advisor regarding Zapata’s methodology and software, reinforcing the Company’s commitment to the scientific rigor of its solution for enterprise customers, government partners and the broader quantum ecosystem.

Paler, Devitt, Izmaylov to Support Critical Layers of the Software Stack

Each new member of the SAB brings expertise in some of the most important and technically challenging areas of Zapata’s quantum software platform, including algorithm benchmarking, error correction architectures and quantum resource estimation—key factors that determine when and how quantum applications become commercially viable.

• Dr. Paler specializes in quantum software, quantum circuit compilation, error correction, and simulation. He was previously a visiting fellow at the University of Texas, Dallas, where his research focused on quantum resource estimation. Dr. Paler also chaired the Quantum Resource Estimation Workshop organized at the International Symposium on Computer Architecture.
• Dr. Devitt’s work has centered on large-scale quantum computing architectures, quantum network systems design, quantum programming development, and quantum error correction. He was appointed as a member of Australia’s National Quantum Advisory Committee in 2022, and he is a Fellow of the Australian Institute of Physics and the Royal Society of New South Wales.
• Dr. Izmaylov’s research focuses on quantum chemistry and methods to reduce the practical bottlenecks in today’s noisy quantum processors. Dr. Izmaylov has made significant contributions to Qubit Coupled Cluster theory and advanced quantum measurement strategies, which have earned him awards like the Google Quantum Research Award and the American Chemical Society’s Journal of Physical Chemistry Lectureship Award.

As the only US-based publicly traded, pure-play quantum software company and only organization to have participated across all technical areas of DARPA’s original Quantum Benchmarking program, Zapata views scientific governance and methodological rigor as core to its responsibility in shaping the quantum software ecosystem.

“The path to large-scale commercially viable quantum applications depends on solving critical bottlenecks in resource estimation, error correction and algorithm design,” said Yudong Cao, CTO of Zapata Quantum. “Dr. Paler, Dr. Devitt and Dr. Izmaylov each bring deep expertise in these exact layers of the stack. Their perspective strengthens our ability to relieve the constraints that limit practical quantum computing today and positions Zapata to play a leading role as the industry transitions to scalable quantum execution.”

Dr. Shor, Dr. Paler, Dr. Devitt and Dr. Izmaylov join Zapata’s existing Scientific Advisory Board members, Dr. Alireza Shabani, Dr. Austin G. Fowler and Dr. Jeff Grover.

To learn more about how Zapata helps organizations discover and develop high-value quantum applications, visit the company’s website.

About Zapata Quantum

Zapata Quantum is a leading hardware-agnostic, pure-play quantum software company focused on accelerating quantum application development. With a portfolio of more than 60 granted and pending patents developed over seven years, Zapata supports applications across cryptography, pharmaceuticals, finance, materials discovery, defense, and more. The Company is the only organization to have participated across all technical areas of DARPA’s Quantum Benchmarking program and has worked with Fortune 500 enterprises and government agencies to translate quantum advances into real-world impact. Learn more at zapataquantum.com.

Media Contact
HKA Marketing Communications
zapata@hkamarcom.com

Investor Relations Contact
Richard Land
investors@zapataquantum.com

TORONTO, Oct. 20, 2026 (GLOBE NEWSWIRE) — Inventus Mining Corp. (TSXV: IVS) (“Inventus” or the “Company”) is pleased to announce that Phase 3 drilling is underway at its 100%-owned Pardo “River of Gold” Project near Sudbury, Ontario. The approximately 6,000-metre, 155-hole program aims to test the extension of Pardo’s multiple gold-bearing layers and expand the area tested by drilling from 1.2 km² to 3.55 km². The program begins as Inventus advances its maiden mineral resource estimate, targeted for mid-November 2026, providing an initial resource foundation to support its Direct Ship Ore (“DSO”) plan while Phase 3 drilling tests the broader scale of the gold system.

HIGHLIGHTS

• Phase 3 drilling commenced on October 14, 2026, with 155 drill holes planned for approximately 6,000 metres of drilling.
• The program aims to expand the area tested by drilling by approximately 196%, from 1.2 km² to 3.55 km².
• Step-out drilling will test the continuation of multiple gold-bearing conglomerate layers, including the sulphide-rich Matinenda Conglomerate (MaC).
• Final Phase 2 drill assays are being received, with the maiden mineral resource estimate targeted for mid-November 2026.

PHASE 3 DRILL PROGRAM

The Phase 3 drill program is designed to significantly expand the area tested by drilling at Pardo (Figure 1). Previous Phase 1 & 2 drilling has intersected gold-bearing conglomerate throughout the existing 1.2 km² area. Phase 3 will test an additional 2.35 km² of favourable geology, testing extensions of the Main Layer and other prospective gold-bearing layers.

MATINENDA CONGLOMERATE EXPLORATION

Phase 3 will also target an area of shallow sulphide-rich gold-bearing Matinenda Conglomerate (MaC) in the western part of the project (Figure 1). Historical drilling in 2009 intersected 7.13 metres grading 0.51 g/t gold, including 2.13 metres grading 1.21 g/t gold, beginning 11 metres below surface in drill hole PD-09-05.

Recent geological analysis has identified a strong positive correlation between visually estimated sulphide content and gold grade within the Matinenda Conglomerate. Inventus will be evaluating whether the sulphide-rich material can be upgraded through ore sorting to produce a higher-grade gold-sulphide concentrate suitable for direct shipping to an existing processing facility.

The Company is also investigating the potential value of a sulphide-gold concentrate for regional smelters. If successful, this opportunity could provide an additional development pathway at Pardo, complementing the Company’s advancing Direct Ship Ore (“DSO”) strategy for the Main Layer. Further testing and commercial evaluation are required to establish feasibility.

MAIDEN MINERAL RESOURCE ESTIMATE

Inventus is receiving the final Phase 2 drill assay results, which will be incorporated into its maiden mineral resource estimate, targeted for completion in mid-November 2026. This initial estimate will cover only the previously drilled area and is intended to provide a resource foundation for advancing the Company’s direct ship ore (DSO) plan. Meanwhile, Phase 3 drilling will focus on expanding the known extent of gold mineralization, with the goal of supporting a potentially larger mineral resource estimate in the future.

Wesley Whymark, CEO & Director, comments: “Phase 3 is an important step toward understanding the full scale of the Pardo gold system. We have encountered gold-bearing conglomerate throughout the area drilled to date, and this program will test a significantly larger area across multiple layers. At the same time, the Matinenda presents an exciting opportunity to potentially develop a second DSO product alongside our more advanced Main Layer. With our maiden resource estimate targeted for mid-November, we are advancing both the exploration potential and development opportunities at Pardo.”

NEXT STEPS

• Report the remaining Phase 2 drilling assays.
• Complete the maiden resource estimate, targeted for mid-November 2026.
• Advance Phase 3 drilling and report results as available.
• Define the next stage of Matinenda metallurgical and ore-sorting testwork.
• Advance plans to resume bulk sampling, with approximately 10,000 tonnes stockpiled and an additional 20,000 tonnes permitted for extraction.
• Continue working toward regulatory approval for tailings placement and evaluating additional long term processing opportunities.
• Updates on the direct ship ore (“DSO”) advancements into 2027.

For further information visit www.inventusmining.com, or contact:

Wesley Whymark
CEO & Director
Inventus Mining Corp.
E-mail: wesley@inventusmining.com
Phone: 705-822-3005

Social Media Accounts

https://x.com/InventusMining
http://ca.linkedin.com/company/inventus-mining
https://www.youtube.com/@inventusmining
https://www.facebook.com/people/Inventus-Mining/61587627317147/

Figure 1. Pardo Phase 3 drill plan showing the previously drilled area of approximately 1.2 km² (blue) and an additional 2.35 km² of planned exploration drilling (purple).

About Inventus Mining Corp.

Inventus is a mineral exploration and development company focused on the world-class mining district of Sudbury, Ontario. We have a 100% interest in our principal assets, the Pardo Paleoplacer Gold Project and the Sudbury 2.0 Critical Mineral Project, located northeast of Sudbury. The Pardo Gold Project is the first important paleoplacer gold discovery in North America. Inventus has approximately 221 million common shares outstanding.

Qualified Person

The Qualified Person responsible for the technical content of this news release is Wesley Whymark, P.Geo., who has reviewed and approved the technical disclosure in this news release on behalf of the Company.

Forward-Looking Statements

This News Release includes certain “forward-looking statements” which are not comprised of historical facts. Forward-looking statements include estimates and statements that describe the Company’s future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “if”, “yet”, “potential”, “undetermined”, “objective”, or “plan”. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to the Company, the Company provides no assurance that actual results will meet management’s expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward-looking information in this news release includes, but is not limited to, the Company’s objectives, goals or future plans, statements, exploration results, potential mineralization, the estimation of mineral resources, exploration and mine development plans, timing of the commencement of operations and estimates of market conditions. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to the failure to identify mineral resources, failure to convert estimated mineral resources to reserves, the inability to complete a feasibility study which recommends a production decision, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, political risks, inability to fulfill the duty to accommodate First Nations and other indigenous peoples, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects, capital and operating costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry, and those risks set out in the Company’s public documents filed on SEDAR+. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

A figure accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/328f21a8-2103-44a1-a7e4-7366d7be08b9

VANCOUVER, British Columbia, Oct. 20, 2026 (GLOBE NEWSWIRE) — GoldInxs Mining Corp. (“GoldInxs,” or the “Company”) (TSXV: INXS, OTCQB: INXGF) is pleased to announce that drilling is underway at its flagship Fishpot Project in Central British Columbia as part of the inaugural drill program intended to test priority targets developed through the convergence of multiple datasets and observations. Previously, a 53.4-line km 3D induced polarization (IP) survey, combined with magnetic data, geochemical sampling, geophysical surveys, geological mapping, and Ripplinger Royalties Corp. Virtual DRILL™ Elemental Harmonic Resonance (“EHR”) interpretations helped refine areas prospective for epithermal gold-silver and porphyry-style copper-gold mineralization, providing the geological and geophysical basis for the Company’s current drilling campaign (refer to press release dated September 24, 2026).

Key Highlights

• Hole 26FP001 has been collared and is actively drilling into the Lightening Zone.
• Phase 1 drilling planned to complete ~2,000 metres of NQ diamond drilling over 8-10 holes.
• Targets include the Lightening, Thriller, Believin’, Luftballon, Southside, and BullsEye zones
• Targeting potential Gold-Copper Porphyry and Blackwater-Style Epithermal mineralization.
• Compelling target convergence at Lightening Zone that features overlapping IP resistivity and chargeability anomalies beneath a reported 2 km by 500 m surface zone of intense silica alteration and associated multi-element geochemical anomalies.
• The program represents the first modern, systematic drill test of multiple priority targets generated through the Company’s integrated exploration program, with only 2 holes of a combined 378 metres of historic drilling on the property.
• Previously reported surface rock samples returned up to 5.65 g/t gold, 11.35 g/t silver and 0.42% copper. These results are not indicative of expected drill grades.

Program Update

Onsite teams have completed trail access construction with the support from local contractors, including the construction of the temporary core logging facility. The diamond drill arrived on site, was set up successfully and is now actively drilling the first planned hole in the Lightening Zone. As the oriented drill core is produced it will be processed by geologists from Tripoint Geological Services, scanned with a handheld portable X-ray Fluorescence (“pXRF”) analyzer, sampled, before being sent for assay at a geochemistry lab.

Figure 1: Diamond drill setting up at Fishpot at the Lightening Zone

Drill Planning Update

Integrating the new and reprocessed geophysical data with the existing property data has allowed the Company to build a list of priority targets as they begin the maiden drill program on the Fishpot Project. Overlapping geological surface information, including geochemistry, alteration, and geological mapping data with new and updated geophysical data has highlighted several promising surface and subsurface anomalies on the property. As drilling continues, active and dynamic interpretation will occur, making each subsequent drill hole a potentially stronger target. The key drill target zones include:

• Lightening Zone: Resistivity (>800ohm-m) and chargeability (>20mV) IP anomaly overlain by a 2km x 500m surface zone of intense silica alteration and overlapping geochemical anomalies including Gold (“Au”), Silver (“Ag”), Copper (“Cu”), Bismuth (“Bi”), Antimony (“Sb”), and Zinc (“Zn”).
• Thriller Zone: Magnetic low zone with resistivity (>800ohm-m) anomaly, silica “ribs” present on surface.
• Believin’ Zone: Resistivity (>800ohm-m) high zone with moderate chargeability (>10mV) anomaly and overlapping magnetic low.
• Southside Zone: Moderate chargeability high (>15mV) with resistivity high (>800Ohm-m) contact, south side of the annular magnetic high.
• BullsEye: Magnetic high zone surrounded by magnetic low with moderate chargeability anomaly, surrounded by an Au, Ag, Cu, Bi, Sb anomaly.

Figure 2: Fishpot exploration target areas

Nick Michael, President and CEO of GoldInxs, commented:

“Commencement of drilling marks a defining milestone for GoldInxs as we transition from target generation to testing our exploration thesis at Fishpot. The Phase 1 program is designed to evaluate multiple priority targets identified through our integrated geological, geochemical, EHR, and geophysical work. The program represents an important step in evaluating the property’s gold-silver and copper-gold potential, with results expected to guide our next exploration decisions.”

Darcy Vis, Vice President Exploration of GoldInxs, commented:

“I am very excited to see the first drill hole starting on the Fishpot Project, it’s been a labour of love to get the project to this point. A lot of work has been put in to generate the best potential targets and now we can see the fruit of our labors coming to light. I was onsite last week helping the team get ready and everyone is working very hard to make the project a success. The next several weeks will be very exciting as we determine what the Fishpot has to show.”

Announcement of Marketing Engagement

The Company announces that it has entered into an engagement with German Mining Networks GmbH (“GMN”) on October 14, 2026, to support the Company’s European investor outreach and shareholder engagement initiatives. The engagement represents a further step in broadening awareness of GoldInxs among international investors. Pursuant to the agreement, GMN will facilitate introductions to prospective investors, including high-net-worth individuals, sector-focused equity fund managers, private wealth managers and family offices across key European financial centres, including Germany, Switzerland, Liechtenstein, Scandinavia and select Eastern European countries. The services may include shareholder targeting calls following significant corporate updates, investor meetings, road show coordination, and related marketing and communication support, subject to investor demand and the terms of the agreement. The agreement has an initial one-month term and automatically renews for successive one-month periods unless terminated in accordance with its terms, with a monthly retainer of C$6,800 and additional fees of C$6,800 for each road show lasting no more than one day, plus applicable expenses and taxes. Through this engagement, GoldInxs aims to expand its international investor reach and strengthen engagement with European capital markets as it works to advance its exploration strategy and build shareholder awareness. GoldInxs and GMN are unrelated entities, and GMN has no present, direct or indirect interest in the Company or its securities. GMN will not receive shares or options as compensation. The contact information for German Mining Networks GmbH is Postfach: 10 01 26, 98561 Schmalkalden, Germany, with primary contact Peter Krah at email: krahp@german-mining.com.

Qualified Person

The technical information in this news release has been reviewed and approved by Darcy Vis, P.Geo., Vice President of Exploration of GoldInxs Mining Corp., who is a Qualified Person as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects. Mr. Vis has verified the data disclosed in this news release through data review including the sampling, analytical and test data underlying the information.

Authorised for release by the Board of GoldInxs Mining Corp.

About GoldInxs

GoldInxs Mining Corp. (TSXV:INXS, OTCQB: INXGF) is a Canadian mineral exploration company focused on discovering and advancing a high-quality gold and copper project in Central British Columbia. The Company’s flagship asset is the Fishpot Property, a large epithermal gold system in central British Columbia with Blackwater-style exploration potential, and in the same region as Artemis Gold’s Blackwater Mine and Evolution Mining’s optioned Clisbako property. The Company is listed on the TSX Venture Exchange under the symbol INXS and on the OTCQB Venture Market under the symbol INXGF, and is led by an experienced management and technical team committed to disciplined exploration and value creation for shareholders.

Website: www.goldinxs.com      |     LinkedIn: LINK      |     Twitter/X: LINK

Further Information:

Barry Miller
Director
GoldInxs Mining Corp.
T: 778.232.1878
E: barry@goldinxs.com

Forward-Looking Statements
This news release contains certain “forward-looking statements” or “forward-looking information” (collectively referred to herein as “forward-looking statements”) within the meaning of applicable securities legislation. Such forward-looking statements are based on a number of assumptions, which may prove to be incorrect. Assumptions have been made regarding, among other things: conditions in general economic and financial markets; accuracy of assay results; geological interpretations from exploration, survey, historic work, drilling results, timing and amount of capital expenditures; performance of available laboratory and other related services; future operating costs; and the historical basis for current estimates of potential quantities and grades of target zones. The actual results could differ materially from those anticipated in these forward-looking statements as a result of risk factors, including the timing and content of work programs; results of exploration activities and development of mineral properties; the interpretation and uncertainties of drilling results and other geological data; receipt, maintenance and security of permits and mineral property titles; environmental and other regulatory risks; project costs overruns or unanticipated costs and expenses; availability of funds; failure to delineate potential quantities and grades of the target zones based on historical data; and general market and industry conditions.

Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. Forward-looking statements in this news release include, but are not limited to, statements regarding the Company’s planned exploration activities at the Fishpot Property or any other Company properties, the timing, scope and objectives of the planned maiden drill program, the anticipated usefulness of geological, geochemical and geophysical data in refining exploration targets, potential exploration results, other prospective exploration projects, regional considerations, potential future financings of the Company and the potential benefits of the Company’s listing on the OTCQB Venture Market.

The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statements were made. The Company undertakes no obligation to update or revise any forward-looking statements included in this news release if these beliefs, estimates and opinions or other circumstances should change, except as otherwise required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/b49ef9a6-fa2e-4098-a1f6-513c3bb014f7
https://www.globenewswire.com/NewsRoom/AttachmentNg/65fee29e-9b36-4592-8cc5-4ecbe1f27afe

TORONTO, Oct. 20, 2026 (GLOBE NEWSWIRE) — Labrador Gold Corp. (TSX.V: LAB | FNR: 2N6) (“LabGold” or the “Company”) is pleased to announce the closing, on October 19, 2026, of the first tranche of its non-brokered private placement offering, first announced on September 17, 2026 and due to strong investor interest, upsized on October 13, 2026 from a maximum of $4,000,000 to a maximum of $7,000,000.

The non-brokered private placement offering consists of: (i) common shares of the Company issued on a non-flow-through basis (the “HD Shares”); and (ii) common shares of the Company that will qualify as “flow-through shares” within the meaning of subsection 66(15) of the Income Tax Act (Canada) (the “Tax Act”) (the “FT Shares” and, together with the HD Shares, the “Shares”), each at a price of $0.05 per Share, for aggregate gross proceeds of a minimum of $2,000,000 and a maximum of $7,000,000, representing the issuance of between 40,000,000 and 140,000,000 Shares (the “Offering”).

The closing of the first tranche comprised subscriptions by Matachewan Consolidated Mines, Limited (TSX.V: MCM-A) (“Matachewan”) and McChip Resources Inc. (TSX.V: MCS) (“McChip” and, together with Matachewan, the “Lead Investors”) for $2,133,790.45 of FT Shares, representing 42,675,809 FT Shares.

The Offering will remain open until the earlier of the sale of the remaining HD Shares and FT Shares and October 23, 2026.

In addition to the statutory hold period expiring February 20, 2027, the FT Shares issued to the Lead Investors are subject to a one-year contractual lock-up, expiring October 19, 2027, subject to customary exceptions.

In connection with the closing of the first tranche and as previously announced on September 17, 2026, Raymond D. Harari has been appointed as a director of the Company. Mr. Harari is the Lead Investors’ initial nominee to the Board of Directors under the investor rights agreement entered into between the Company and the Lead Investors (the “Investor Rights Agreement”). The Lead Investors have the right to nominate a second director to the Board of Directors of the Company at the next annual meeting to be held on or before April 30, 2027. As previously disclosed in the Company’s news release dated September 17, 2026, the Company had intended to appoint Mr. Harari as President effective upon closing. The Investor Rights Agreement no longer provides for that appointment, and, while Mr. Harari has not been appointed as President at this time, he may be appointed President in the future.

Mr. Harari is the founder of Canalis Capital, a merchant bank focused on the resource sector and currently serves as President and director of Argentina Metals Corp. (TSXV listed) and director of Lunex Metals Corp. (TSXV listed) and Bolivar Gold (private). He has served as a senior executive and director of a number of publicly listed mineral exploration companies including Hercules Metals Corp., Westward Gold Inc. and Sendero Resources Corp.

The Investor Rights Agreement is a customary agreement providing the Lead Investors with the right to nominate two directors to the Board of Directors of the Company along with certain information, participation and top-up rights for so long as the Lead Investors and their permitted transferees collectively hold at least 10% of the issued and outstanding common shares of the Company. The participation and top-up rights are intended to permit the Lead Investors, subject to customary exclusions, applicable law, acceptance of the TSX Venture Exchange (the “TSXV”) and a maximum ownership level of 19.99% unless any required shareholder approval is obtained, to maintain their collective pro rata ownership percentage in connection with subsequent issuances of securities by the Company. Any further Shares acquired by the Lead Investors under the Offering will also be subject to a one-year contractual lock-up, subject to customary exceptions. The requirement that the Lead Investors vote the common shares of the Company held by them in favour of the existing Board of Directors, and the Lead Investors’ nominees, at the next annual meeting has been removed from the Investor Rights Agreement. Additionally, the requirement that for a period of two years, the Lead Investors vote in favour of the election of Roger Moss and Leo Karabelas as directors of the Company, has also been removed.

The Offering

The Offering consists of the Shares, each at a price of $0.05 per Share, for aggregate gross proceeds of a maximum of $7,000,000, representing the issuance of up to 140,000,000 Shares.

The final tranche of the Offering will close on or about October 23, 2026. The participants in, and the number of HD Shares and FT Shares to be issued under, the final tranche will be determined by the Company and the Lead Investors, provided that the aggregate gross proceeds of the Offering will not exceed $7,000,000. In the final tranche, the Lead Investors intend to subscribe for HD Shares such that, together with the FT Shares acquired in the first tranche, the Lead Investors will collectively hold up to 19.99% of the issued and outstanding common shares of the Company following completion of the Offering.

The gross proceeds from the sale of the FT Shares will be used to incur eligible “Canadian exploration expenses” that qualify as “flow-through mining expenditures”, as those terms are defined in the Tax Act (the “Qualifying Expenditures”), on the Company’s mineral properties in Canada. The Company will renounce the Qualifying Expenditures in favour of the subscribers of the FT Shares with an effective date no later than the date permitted under the Tax Act, in an aggregate amount not less than the gross proceeds raised from the issuance of the FT Shares. The net proceeds from the sale of the HD Shares will be used for exploration and development activities, working capital and general corporate purposes.

All securities issued under the Offering will be subject to a hold period of four months and one day from the date of issuance in accordance with applicable Canadian securities laws and the policies of the TSXV. The Offering remains subject to final acceptance of the TSXV. The Company does not intend to pay finder’s fees in connection with the Offering.

The securities referred to in this news release have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or the securities laws of any state of the United States, and may not be offered or sold in the United States absent registration or an available exemption from the registration requirements of the U.S. Securities Act and applicable securities laws of any state of the United States. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities in any jurisdiction.

Four insiders of the Company intend to subscribe for 8,700,000 FT Shares and 3,000,000 HD Shares for an aggregate of $585,000 on the closing of the final tranche. The insider private placements are exempt from the valuation and minority shareholder approval requirements of Multilateral Instrument 61-101 (“MI 61-101”) by virtue of the exemptions contained in sections 5.5(a) and 5.7(1) (a) of MI 61-101 in that the fair market value of the consideration for the securities of the Company which will be issued to the insiders will not exceed 25% of its market capitalization.

About Labrador Gold

Labrador Gold is a Canadian-based hybrid mining and investment issuer focused on the acquisition and exploration of prospective mineral projects in Canada and on strategic investments in mining companies and assets that the Company believes have the potential to generate long-term value.

The Mariposa project covers 16,000 ha in the White Gold District and is 40 kilometres southeast of the White Gold Project and 30 kilometres east-northeast of Fuerte’s Coffee gold project. Mariposa shares many geological similarities to both the Golden Saddle (part of the White Gold Project) and Coffee gold deposits including host lithologies, mineralization style and structural control. The property occurs at the headwaters of significant placer gold producing creeks with historic placer production of 73,000 oz from Scroggie Creek (3) indicative of significant bedrock gold mineralization yet to be fully defined. Six significant gold occurrences have been delineated by over 13,000 soil samples to date, including the most advanced Skookum Main and Skookum West prospects.

The Watson Project, a joint venture with Nemo Resources Inc., represents the largest landholding in the Fort Hope Greenstone Belt which is significantly underexplored compared to other greenstone belts (e.g. Red Lake and Pickle Lake) in northwestern Ontario. While the exploration focus will be on gold, the Watson project also hosts significant potential for critical minerals (e.g. antimony, nickel, copper and zinc). The proposed road to the Ring of Fire, expected to begin construction in mid-2026, runs through the Watson property and, once complete, will significantly reduce exploration and development costs.

The Hopedale property covers much of the Archean-age Florence Lake greenstone belt, which extends over 60 kilometers. While typical of greenstone belts globally, the area has been underexplored. LabGold’s work to date has identified gold anomalies in rocks, soils, and lake sediments across a three-kilometer section of the northern portion of the belt. Five gold occurrences lie along this trend, four of which were discovered by LabGold. Additional anomalous gold values occur across approximately 40 kilometers of the southern portion of the belt. Recent exploration has also demonstrated potential for copper, nickel, and cobalt.

The Borden Lake project near Chapleau, Ontario lies immediately southeast of Discovery Silver Corp’s Borden gold mine. Past exploration by LabGold identified two anomalous gold zones based on geochemistry and geophysics.

The Company has 213,485,788 common shares issued and outstanding and trades on the TSX Venture Exchange under the symbol LAB.

For more information, please contact:

Roger Moss, President and CEO

Tel: 416-704-8291

Website: www.labradorgold.com

X: @LabGoldCorp

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws. Forward-looking statements in this release include, but are not limited to, statements regarding the completion, size, pricing, structure and timing of the Offering, including the closing of the final tranche; the number and composition of Shares to be issued under the Offering; the participation of the Lead Investors, insiders and other subscribers; the anticipated use of the proceeds of the Offering; the Company’s intention to incur and renounce Qualifying Expenditures; and the receipt of corporate and TSXV approvals.

Forward-looking statements are based on management’s current expectations, estimates, assumptions and beliefs as of the date of this release, including assumptions regarding the satisfaction of the conditions to closing; the availability of applicable prospectus exemptions; the receipt of all required corporate and regulatory approvals, including the acceptance of the TSXV; the availability of sufficient subscriber demand; the ability of subscribers to fund their subscriptions; the absence of a material adverse change before closing; the availability of Qualifying Expenditures; and the Company’s ability to incur and renounce the Qualifying Expenditures within the periods required under the Tax Act.

Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, the risk that the Offering may be delayed, reduced, restructured or not completed on the terms described or at all; that the Company may raise less than the maximum amount contemplated; that subscribers may withdraw or fail to fund their subscriptions; that required corporate or regulatory approvals, including TSXV acceptance, may not be obtained; that sufficient Qualifying Expenditures may not be available; that the Company may not incur or renounce Qualifying Expenditures within the periods required under the Tax Act; and the risks described in the Company’s continuous disclosure filings with Canadian securities regulatory authorities.

Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.